SCHEMBL15968660

SCHEMBL15968660

CCOc1c(F)cc(C(=O)O)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.56
POLB P06746 2/20 0.56
ALOX15 P16050 1/20 0.56
PLAU P00749 1/20 0.55
LMNA P02545 3/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
TPMT P51580 1/20 0.49
GAA P10253 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
ABL1 P00519 1/20 0.48
MAPT P10636 1/20 0.48
RIN1 Q13671 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TDP1 Q9NUW8 2/20 0.46
MCL1 Q07820 1/20 0.46
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1457769 0.88 PLAU (0.64) HTTPOLBALOX15PLAULMNA
SCHEMBL1012426 0.88 PDE5A (0.46) HTTPOLBALOX15PLAULMNA
SCHEMBL1420745 0.82 HTT (0.78) HTTPOLBALOX15PLAULMNA
SCHEMBL1457795 0.81 TPMT (0.67) HTTPOLBALOX15PLAULMNA
SCHEMBL1458056 0.80 HTT (0.52) HTTPOLBALOX15PLAULMNA
SCHEMBL3225429 0.80 PLAU (0.51) HTTPOLBALOX15PLAUMEN1
SCHEMBL1457711 0.79 HTT (0.66) HTTPOLBALOX15PLAULMNA
SCHEMBL1707509 0.79 HTT (0.55) HTTPOLBALOX15PLAULMNA
SCHEMBL27883396 0.77 TPMT (0.49) HTTPOLBALOX15PLAULMNA
SCHEMBL16400749 0.76 HTT (0.43) HTTPOLBALOX15PLAULMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 US disclosed
EP-2772485-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-09-03 EP disclosed
US-20140243310-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243310-A1 BICYCLIC COMPOUND BICRA, NR3C2, CYP11B2 HTT 3054/4885POLB 4235/4885ALOX15 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.